Remembering Dr. Craig Leonardi
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
Thursday, October 29, 2026
Assessments
A list of commonly used measurement tools for psoriasis management and clinical trials.
GENERAL
DermSat-7
The DermSat-7 is a patient-reported outcome measure designed to assess patient satisfaction with psoriasis treatment. It consists of seven key questions evaluating treatment effectiveness, convenience, and overall satisfaction, providing valuable insights for both patients and healthcare providers.
DLQI: Dermatology Quality of Life Index
A simple 10-question validated questionnaire that has been used for more than 40 different skin conditions in over 80 countries and is available in over 110 languages to measure disease severity and quality of life.
OPAT™: The Optimal Psoriasis Assessment Tool
A simple proxy for PASI and DLQI using body surface area (BSA) and one or more of Skin Pain Visual Analog Score (Skin Pain VAS), Itch numeric rating scale (Itch NRS), and patient global assessment (patGA).
PASI: Psoriasis Area and Severity Index
Quantifies the severity of psoriasis measured by redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
PGA: Physician's Global Assessment
Physician’s assessment of the severity of disease based on a scale from clear to very severe.
PSI: Psoriasis Symptom Inventory
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic plaque psoriasis.
SPI: Simplified Psoriasis Index
The Simplified Psoriasis Index (SPI) is a tool that has been developed to enable either healthcare professionals or patients with psoriasis to make regular assessments of disease severity and its impact on well-being. It also incorporates a summary of past behavior and treatment.
SPECIAL AREAS & POPULATIONS
CDLQI: The Children's Dermatology Life Quality Index
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version and the Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
GET THE CDLQI
DOWNLOAD THE OFFICIAL APP (free) – Apple
DOWNLOAD THE OFFICIAL APP (free) – Google Play
Nail Psoriasis Severity Index (NAPSI)
A clinical tool used to assess the severity of nail psoriasis, focusing on specific features of nail involvement.
Palmoplantar Psoriasis Global Assessment (PPPGA)
A clinical tool for evaluating the severity of psoriasis on the hands and feet. Based on erythema, scaling, and pustule presence, the PPPGA ranges from clear to severe.
PEST: Psoriasis Epidemiology Screening Tool
A validated screening tool for psoriatic arthritis (PsA). It is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
Psoriasis Scalp Severity Index (PSSI)
A clinical assessment tool used to measure the severity of psoriasis specifically on the scalp, based on erythema, scaling, and thickness.
sPGA-G: Static Physician's Global Assessment of Genitalia
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis.
RESOURCES
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Score
A validated online measure designed to comprehensively evaluate disease activity in generalized pustular psoriasis, providing clinicians with a reliable tool to assess the severity and progression of the condition.
Clinical Disease Measures in Generalized Pustular Psoriasis
Includes validated tools that help clinicians accurately monitor disease severity, progression, and treatment response.
The Psychometric Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) and Generalized Pustular Psoriasis Area and Severity Index (GPPASI)
This confirms the reliability and accuracy in assessing disease severity and extent, providing essential tools for clinicians to effectively evaluate and manage generalized pustular psoriasis.
IPC does not endorse or accept any responsibility for the content of external websites.